Takayoshi Yamauchi

Takayoshi Yamauchi

Auto-generated profile, based on publicly available information

Takayoshi Yamauchi

Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Cell
Verified
Journal Article
Closed access
YYYang Yang
Yang Yang
BLBei Liu
Bei Liu
JXJun Xu
Jun Xu
JWJinlin Wang
Jinlin Wang
JWJun Wu
Jun Wu
HDHongkui Deng
Hongkui Deng

1 January 2017 in Cell
Verified
Journal Article
Closed access
JWJun Wu
Jun Wu
APAida Platero-Luengo
Aida Platero-Luengo
MSMasahiro Sakurai
Masahiro Sakurai
ASAtsushi Sugawara
Atsushi Sugawara
MGMaria Antonia Gil
Maria Antonia Gil
Juan Carlos Izpisua BelmonteJuan Carlos Izpisua Belmonte
Juan Carlos Izpisua Belmonte

1 December 2017 in Cell
Verified
Journal Article
Closed access
HLHsin-Kai Liao
Hsin-Kai Liao
FHFumiyuki Hatanaka
Fumiyuki Hatanaka
TAToshikazu Araoka
Toshikazu Araoka
PRPradeep Reddy
Pradeep Reddy
MWMin-Zu Wu
Min-Zu Wu
Juan Carlos Izpisua BelmonteJuan Carlos Izpisua Belmonte
Juan Carlos Izpisua Belmonte

3 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
TYTakayoshi Yamauchi
Takayoshi Yamauchi
THToshifumi Hoki
Toshifumi Hoki
TOTakaaki Oba
Takaaki Oba
VJVaibhav Jain
Vaibhav Jain
HCHongbin Chen
Hongbin Chen
FIFumito Ito
Fumito Ito
Immune checkpoint inhibitors (ICI) have revolutionized treatment for various cancers; however, durable response is limited to only a subset of patients. Discovery of blood-based biomarkers that reflect dynamic change of the tumor microenvironment, and predict response to ICI, will markedly improve current treatment regimens. Here, we investigate CX3C chemokine receptor 1 (CX3CR1), a marker of T-cell differentiation, as a predictive correlate of response to ICI therapy. Successful treatment of tumor-bearing mice with ICI increases the frequency and T-cell receptor clonality of the peripheral CX3CR1+CD8+ T-cell subset that includes an enriched repertoire of tumor-specific and tumor-infiltrating CD8+ T cells. Furthermore, an increase in the frequency of the CX3CR1+ subset in circulating CD8+ T cells early after initiation of anti-PD-1 therapy correlates with response and survival in patients with non-small cell lung cancer. Collectively, these data support T-cell CX3CR1 expression as a blood-based dynamic early on-treatment predictor of response to ICI therapy.

23 April 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
TYTakayoshi Yamauchi
Takayoshi Yamauchi
THToshifumi Hoki
Toshifumi Hoki
TOTakaaki Oba
Takaaki Oba
HSHidehito Saito
Hidehito Saito
KAKristopher Attwood
Kristopher Attwood
FIFumito Ito
Fumito Ito
Although blockade of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint has revolutionized cancer treatment, how it works on tumor-infiltrating CD8 + T cells recognizing the same antigen at various differentiation stages remains elusive. Here, we found that the chemokine receptor CX3CR1 identified 3 distinct differentiation states of intratumor CD8 + T cell subsets. Adoptively transferred antigen-specific CX3CR1 – CD8 + T cells generated phenotypically and functionally distinct CX3CR1 int and CX3CR1 hi subsets in the periphery. Notably, expression of coinhibitory receptors and T cell factor 1 (Tcf1) inversely correlated with the degree of T cell differentiation defined by CX3CR1. Despite lower expression of coinhibitory receptors and potent cytolytic activity, in vivo depletion of the CX3CR1 hi subset did not alter the antitumor efficacy of adoptively transferred CD8 + T cells. Furthermore, differentiated CX3CR1 int and CX3CR1 hi subsets were impaired in their ability to undergo proliferation upon restimulation and had no impact on established tumors upon second adoptive transfer compared with the CX3CR1 – subset that remained effective. Accordingly, anti–PD-L1 therapy preferentially rescued proliferation and cytokine production of the CX3CR1 – subset and enhanced antitumor efficacy of adoptively transferred CD8 + T cells. These findings provide a better understanding of the phenotypic and functional heterogeneity of tumor-infiltrating CD8 + T cells and can be exploited to develop more effective immunotherapy.

30 April 2019 in Cells
Verified
Journal Article
Open access
PDF file
TYTakayoshi Yamauchi
Takayoshi Yamauchi
TMToshiro Moroishi
Toshiro Moroishi
The Hippo pathway was originally identified as an evolutionarily-conserved signaling mechanism that contributes to the control of organ size. It was then rapidly expanded as a key pathway in the regulation of tissue development, regeneration, and cancer pathogenesis. The increasing amount of evidence in recent years has also connected this pathway to the regulation of innate and adaptive immune responses. Notably, the Hippo pathway has been revealed to play a pivotal role in adaptive immune cell lineages, as represented by the patients with T- and B-cell lymphopenia exhibiting defective expressions of the pathway component. The complex regulatory mechanisms of and by the Hippo pathway have also been evident as alternative signal transductions are employed in some immune cell types. In this review article, we summarize the current understanding of the emerging roles of the Hippo pathway in adaptive immune cell development and differentiation. We also highlight the recent findings concerning the dual functions of the Hippo pathway in autoimmunity and anti-cancer immune responses and discuss the key open questions in the interplay between the Hippo pathway and the mammalian immune system.